Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15201800 | 0.99 | LTA4H (0.67) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL321314 | 0.88 | NOX1 (0.62) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL6688599 | 0.86 | NOX1 (0.61) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL15201156 | 0.85 | NOX1 (0.60) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL21295527 | 0.84 | MEN1 (0.77) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL7092234 | 0.83 | NOX1 (0.70) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL14280159 | 0.83 | LTA4H (0.71) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL4666213 | 0.82 | RAB9A (0.66) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL21067416 | 0.81 | LTA4H (1.00) | LTA4HNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL4406536 | 0.81 | EPHX1 (0.62) | CA12CA1CA2CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261178-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | MISTRY SHAILESH (GB) | 2013-10-03 | — | — | US | disclosed |
| EP-2590937-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | The University Of Nottingham (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004549-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261178-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | NR3C2, NPR3, ADRB3 | LTA4H 2032/4885CA12 1865/4885CA1 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.